share_log

迈博药业-B(02181.HK):2023年净亏损2.09亿元

Maibo Pharmaceutical-B (02181.HK): net loss of 209 million yuan in 2023

Gelonghui Finance ·  Mar 26 07:58

On March 26, Ge Longhui | Maibo Pharmaceutical-B (02181.HK) announced that for the year ended December 31, 2023, the Group's revenue increased 55.9% year-on-year to RMB 87.161 million, mainly due to a sharp increase in drug sales revenue during the reporting period compared to last year. Losses attributable to company owners were approximately RMB 209 million, while losses attributable to company owners during the same period last year were approximately RMB 211 million, with a basic loss of RMB 0.05 per share.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment